📰 Ryan Gynne News

Ryan Gynne News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Ryan Gynne. Real-time updates on events, politics, business and more.

Otsuka announces NICE recommendation of Lupkynis® (voclosporin) with mycophenolate mofetil for treating active lupus nephritis

May 3, 2023

Otsuka announces NICE recommendation of Lupkynis&reg;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (voclosporin) with mycophenolate mofetil for treating active lupus nephritis&nbsp;LONDON, UK, 3 May 2023 &ndash; Otsuka Pharmaceuticals (U.K.) Ltd. announces that the National Institute for Health and C...

Northern Ireland United Kingdom City Of Great Britain Otsuka Europe Ryan Gynne

Source: pharmiweb.com

Otsuka's Lupkynis receives NICE green light

May 3, 2023

Recommendation applies across England and Wales and the treatment is available now - News - PharmaTimes

United Kingdom Great Britain Paul Howard Ryan Gynne Otsuka Pharmaceuticals Healthcare Products Regulatory Agency

Source: pharmatimes.com

Otsuka announces MHRA authorisation of Lupkynis® (voclosporin) as first oral calcineurin-inhibitor ▼ (CNI) for active lupus nephritis

December 1, 2022

Otsuka Pharmaceuticals UK Ltd. announces that the MHRA (Medicines and Healthcare Products Regulatory Agency) has authorised Lupkynis® (voclosporin) for use in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus ...

United Kingdom Northern Ireland City Of Great Britain Otsuka Europe Ryan Gynne

Source: pharmiweb.com

Otsuka receives vital Lupkynis MHRA authorisation

November 30, 2022

Therapy represents first oral calcineurin-inhibitor treatment for active lupus nephritis in adults - News - PharmaTimes

United Kingdom Ryan Gynne Healthcare Products Regulatory Agency

Source: pharmatimes.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation